• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Broadfoot Jill Marie

    6/6/25 4:00:04 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CUE alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Broadfoot Jill Marie

    (Last) (First) (Middle)
    C/O CUE BIOPHARMA, INC.
    40 GUEST STREET

    (Street)
    BOSTON MA 02135

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/04/2025
    3. Issuer Name and Ticker or Trading Symbol
    Cue Biopharma, Inc. [ CUE ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24.1 - Power of Attorney
    No securities are beneficially owned.
    /s/ Jill Marie Broadfoot by Colin Sandercock, attorney-in-fact 06/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CUE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CUE

    DatePrice TargetRatingAnalyst
    3/13/2024$6.00Buy
    Jefferies
    6/26/2023$10.00Outperform
    Oppenheimer
    11/21/2022$7.00Overweight
    Piper Sandler
    1/13/2022$20.00Buy
    H.C. Wainwright
    1/3/2022$28.00Buy
    Craig Hallum
    More analyst ratings

    $CUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Broadfoot Jill Marie

    4 - Cue Biopharma, Inc. (0001645460) (Issuer)

    6/6/25 4:00:05 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Broadfoot Jill Marie

    3 - Cue Biopharma, Inc. (0001645460) (Issuer)

    6/6/25 4:00:04 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CHIEF FINANCIAL OFFICER Millar Kerri-Ann

    4 - Cue Biopharma, Inc. (0001645460) (Issuer)

    3/25/25 4:00:10 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    SEC Filings

    View All

    SEC Form S-8 filed by Cue Biopharma Inc.

    S-8 - Cue Biopharma, Inc. (0001645460) (Filer)

    8/12/25 4:11:48 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Cue Biopharma Inc.

    10-Q - Cue Biopharma, Inc. (0001645460) (Filer)

    8/12/25 4:00:53 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Cue Biopharma, Inc. (0001645460) (Filer)

    8/12/25 4:00:29 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Cue Biopharma with a new price target

    Jefferies initiated coverage of Cue Biopharma with a rating of Buy and set a new price target of $6.00

    3/13/24 7:30:48 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer resumed coverage on Cue Biopharma with a new price target

    Oppenheimer resumed coverage of Cue Biopharma with a rating of Outperform and set a new price target of $10.00

    6/26/23 7:24:09 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Cue Biopharma with a new price target

    Piper Sandler initiated coverage of Cue Biopharma with a rating of Overweight and set a new price target of $7.00

    11/21/22 7:39:31 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

    First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, announced today the initiation of an investigator sponsored trial (IST) in rGBM at the DFCI with the first patient in the trial having been dosed with CUE-102. The trial (NCT06917885) is a Phase 1b, open-label study of adjuvant CUE-102, the Company's drug product candidate targeting Wilms' Tumor 1

    8/13/25 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

    Received FDA feedback on Pre-IND Briefing Document reinforcing Company's intention to advance investigational new drug (IND) submission for CUE-401 to address unmet need in the treatment of autoimmune disease. Announced strategic research collaboration and license agreement with Boehringer Ingelheim to develop and commercialize CUE-501, a differentiated B cell depletion therapy for autoimmune and inflammatory diseases. Upfront payment of $12 million and ~$345 million in potential milestone payments Raised approximately $20 million through a public offering. BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage bio

    8/12/25 4:05:00 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 23, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer diagnoses are climbing fastest among younger women, sparking alarm that looming cuts to U.S. research budgets could stall progress in prevention and treatment. Adding to the strain, federal and state regulators are re‑examining mRNA vaccines, creating a cloud of uncertainty over future cancer‑funding priorities. Yet even amid this policy turbulence, a new wave of oncology innovators is lining up near‑term milestones that could reshape the landscape—led by Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Cue Biopharma, Inc. (NASDAQ:CUE)

    7/23/25 9:26:00 AM ET
    $ALLO
    $CATX
    $CUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    $CUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Passeri Daniel R bought $30,900 worth of shares (30,000 units at $1.03), increasing direct ownership by 22% to 164,578 units (SEC Form 4)

    4 - Cue Biopharma, Inc. (0001645460) (Issuer)

    12/18/24 4:00:04 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Leadership Updates

    Live Leadership Updates

    View All

    Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

    BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the appointment of industry veteran Lucinda Warren as chief business officer (CBO). With an extensive background and proven expertise in strategic transactions, portfolio optimization and alliance management through her extensive tenure at Johnson & Johnson and Jansen, Ms. Warren will play a pivotal role in advancing Cue Biopharma's core corporate objectives following the company's recent business restructuring and autoimmune program prioritizati

    9/9/24 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors

    BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today the appointment of seasoned pharmaceutical executive Pamela D. Garzone, Ph.D., to its board of directors. Dr. Garzone brings to Cue Biopharma more than 25 years of healthcare and pharmaceutical industry experience in drug development, including strategic, scientific, clinical and regulatory leadership expertise. "We are pleased to have Dr. Garzone join our board of directors," said Daniel Passeri, chief executive

    4/25/23 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

    BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today the appointment of industry veteran Patrick Verheyen to its board of directors (BOD). Mr. Verheyen brings to Cue Biopharma more than 35-years of experience facilitating pipeline growth and innovation programs at Janssen Pharmaceutical Companies of Johnson and Johnson. "We are very pleased to welcome Mr. Verheyen to our BOD and leverage his extensive experience and guidance as we seek to enhance and broaden Cue Bi

    4/12/23 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Financials

    Live finance-specific insights

    View All

    Cue Biopharma to Host Business Update Call and Webcast

    BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it will host a conference call and webcast to provide a business update on Tuesday, April 15, 2025 at 4:30 p.m. ET. Conference Call and Webcast DetailsTuesday, April 15 at 4:30 p.m. ET Investors:1-844-826-3035International Investors:1-412-317-5195Conference ID:10199037Webcast Link:https://viavid.webcasts.com/starthere.jsp?ei=1715808&tp_key=9378826572 The live and archived webcast will also b

    4/14/25 5:02:00 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma to Host Business Update Call and Webcast

    BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, August 19, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website. The company will provide a business overview of its recent restructuring and near-term strategic prioritization objectives. The discussion will focus on the company's approach to enhance near-term shareholder value by refocusing resourc

    8/13/24 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma to Host Business Update Call and Webcast

    BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, April 8, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website. The Company will provide a corporate update highlighting measurable progress advancing its lead clinical oncology programs, CUE-101 and CUE-102, its lead preclinical autoimmune program CUE-401 partnered with Ono Pharmaceutical, as well as additional au

    4/2/24 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cue Biopharma Inc.

    SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)

    3/11/24 6:40:41 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cue Biopharma Inc.

    SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)

    2/7/24 5:09:04 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cue Biopharma Inc.

    SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)

    1/31/24 2:08:28 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care